tiprankstipranks
Trending News
More News >
Hydrix Limited (AU:HYD)
ASX:HYD
Australian Market

Hydrix Limited (HYD) AI Stock Analysis

Compare
2 Followers

Top Page

AU

Hydrix Limited

(Sydney:HYD)

Rating:40Underperform
Price Target:
AU$0.00
▼(-100.00%Downside)
Hydrix Limited's overall stock score is driven primarily by its poor financial performance and unfavorable valuation metrics. The company faces significant financial challenges, with negative profit margins and high leverage. Technical analysis also points to weak momentum and bearish conditions, further impacting the score. The lack of earnings call and corporate events data means these components do not influence the overall assessment.

Hydrix Limited (HYD) vs. iShares MSCI Australia ETF (EWA)

Hydrix Limited Business Overview & Revenue Model

Company DescriptionHydrix Limited provides product design, engineering, and regulatory services in Australia, Singapore, Europe, North America, and internationally. It operates through two segments: Hydrix Services and Hydrix Medical. It provides cardiovascular products, such as The GUARDIAN, a cardiac monitoring and alerting device that reduces the stresses of living; Phyzhon PHYRARI FFR-Wire enables cardiologists to combine diagnosis procedures with delivery of therapy including stents; and LUDO, a customizable plug-and-play platform that provides critical tools to start MCS pump development. The company also offers a range of services, including product development, regulatory and clinical consulting, and technology commercialization. It serves medical, consumer, industrial, utilities, defense, aerospace, and mining industries. The company was formerly known as Panorama Synergy Limited and changed its name to Hydrix Limited in November 2018. Hydrix Limited was incorporated in 1993 and is headquartered in Mulgrave, Australia
How the Company Makes MoneyHydrix Limited generates revenue through a diversified model primarily focused on service fees and product sales. The company earns income by providing engineering and design services for the development of complex products, particularly in the medical technology sector. Additionally, Hydrix engages in licensing arrangements and partnerships that allow it to commercialize innovative technologies. Another significant revenue stream comes from the sale of proprietary products and solutions, developed either in-house or through collaborations. The company's financial performance is further bolstered by strategic partnerships with leading firms in the medical and safety technology fields, enhancing its ability to deliver comprehensive solutions and expand its market reach.

Hydrix Limited Financial Statement Overview

Summary
Hydrix Limited faces substantial financial challenges, including declining revenues, negative profit margins, high leverage, and cash flow deficiencies. The company needs to address operational inefficiencies and improve its capital structure to stabilize its financial health.
Income Statement
40
Negative
Hydrix Limited's income statement indicates financial challenges, with declining revenue and negative profit margins. The company reported a significant net loss, and both EBIT and EBITDA margins are negative, reflecting operational inefficiencies. The revenue growth rate is negative, showing a downward trend in sales.
Balance Sheet
35
Negative
The balance sheet reveals a precarious financial position, with negative stockholders' equity indicating potential solvency issues. The high debt-to-equity ratio highlights significant leverage, increasing financial risk. The equity ratio is also negative, suggesting that liabilities exceed assets.
Cash Flow
45
Neutral
Cash flow analysis shows persistent negative free cash flow, indicating the company is not generating sufficient cash to cover its capital expenditures. The operating cash flow to net income ratio is unfavorable, reflecting cash flow challenges. However, some relief is provided by positive financing cash flow.
BreakdownTTMJun 2024Jun 2023Jun 2022Jun 2021Jun 2020
Income Statement
Total Revenue10.32M10.61M13.16M10.33M7.45M14.93M
Gross Profit9.68M9.79M-638.73K-3.31M-6.46M569.70K
EBITDA-2.50M-7.92M1.30M-4.05M-6.34M-1.23M
Net Income-6.40M-9.56M-396.93K-5.55M-9.78M-3.22M
Balance Sheet
Total Assets9.09M8.62M14.58M15.94M19.38M20.50M
Cash, Cash Equivalents and Short-Term Investments1.12M914.27K1.15M1.94M6.65M1.69M
Total Debt7.61M7.61M4.73M5.40M5.97M9.92M
Total Liabilities12.89M11.98M8.22M12.66M13.67M18.20M
Stockholders Equity-3.79M-3.36M6.35M3.28M5.71M2.30M
Cash Flow
Free Cash Flow-367.89K-1.91M-3.32M-6.75M-3.35M-1.37M
Operating Cash Flow-359.81K-1.89M-3.12M-6.58M-2.86M-1.32M
Investing Cash Flow157.07K-53.43K-209.71K-306.65K-641.56K-1.07M
Financing Cash Flow471.87K1.71M2.54M2.18M8.46M3.84M

Hydrix Limited Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.02
Negative
200DMA
0.01
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
43.10
Neutral
STOCH
-77.78
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AU:HYD, the sentiment is Negative. The current price of 0.01 is below the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.01, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 43.10 is Neutral, neither overbought nor oversold. The STOCH value of -77.78 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AU:HYD.

Hydrix Limited Peers Comparison

Overall Rating
UnderperformOutperform
Sector (63)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
63
Neutral
$33.22B5.99-11.76%1.91%5.54%-19.87%
AUHYD
40
Underperform
AU$3.55M-637.73%-13.05%-184.09%
$262.09M-133.28%
$1.73M-119.28%
AURHT
62
Neutral
AU$17.93M140.00-3.11%89.13%69.57%
AUPYC
50
Neutral
AU$740.74M-112.97%-84.82%
AU4DX
39
Underperform
AU$111.72M-52.37%471.29%-4.58%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
AU:HYD
Hydrix Limited
0.01
0.00
0.00%
BRCHF
BrainChip Holdings
0.14
>-0.01
-6.67%
BITRF
Biotron Limited
0.05
0.02
66.67%
AU:PYC
PYC Therapeutics Limited
1.27
0.08
6.72%
AU:RHT
Resonance Health Ltd
0.04
-0.02
-33.33%
AU:4DX
4DMedical Ltd
0.24
-0.30
-55.56%

Hydrix Limited Corporate Events

Hydrix Limited Announces Cessation of Securities
Apr 14, 2025

Hydrix Limited announced the cessation of 11,250 securities due to the lapse of conditional rights, as the conditions for these securities were not met by the deadline of March 31, 2025. This announcement may impact the company’s capital structure and could have implications for its stakeholders, reflecting on the company’s strategic adjustments in managing its securities.

Hydrix Limited Announces Cessation of Securities
Apr 14, 2025

Hydrix Limited announced the cessation of 10,000 securities due to the lapse of conditional rights, as the conditions were not met or became incapable of being satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders regarding the company’s financial strategies and market positioning.

Hydrix Limited Announces Cessation of Securities
Apr 14, 2025

Hydrix Limited announced the cessation of certain securities due to the lapse of conditional rights, as the conditions were not met. This cessation involves 3,150 options that were set to expire in June 2027, impacting the company’s issued capital and potentially affecting investor perceptions of its financial strategies.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Jun 26, 2025